about
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infantsT cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian childrenGenome-wide association study indicates two novel resistance loci for severe malariaEffect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trialEvaluating health research capacity building: an evidence-based toolEvaluation of a learner-designed course for teaching health research skills in GhanaRandomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children.Breast cancer in Sub-Saharan Africa: opportunities for prevention.Cancer incidence in Ghana, 2012: evidence from a population-based cancer registryExploring the relationship between chronic undernutrition and asymptomatic malaria in Ghanaian childrenDisease-associated QT-shortage versus quinine associated QT-prolongation: age dependent ECG-effects in Ghanaian children with severe malaria.A -436C>A polymorphism in the human FAS gene promoter associated with severe childhood malariaAssessment of severe malaria in a multicenter, phase III, RTS, S/AS01 malaria candidate vaccine trial: case definition, standardization of data collection and patient carePopulation pharmacokinetics of intramuscular quinine in children with severe malariaDelayed hemolysis after treatment with parenteral artesunate in African children with severe malaria--a double-center prospective study.A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine.Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children.The outcome of a test-treat package versus routine outpatient care for Ghanaian children with fever: a pragmatic randomized control trialImproving access to malaria medicine through private-sector subsidies in seven African countries.Endothelial protein C receptor gene variants not associated with severe malaria in ghanaian children.Severe malaria in children leads to a significant impairment of transitory otoacoustic emissions--a prospective multicenter cohort study.Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria VaccineA randomized trial on effectiveness of artemether-lumefantrine versus artesunate plus amodiaquine for unsupervised treatment of uncomplicated Plasmodium falciparum malaria in Ghanaian children.Sickle cell disease: management options and challenges in developing countries.Communicating the AMFm message: exploring the effect of communication and training interventions on private for-profit provider awareness and knowledge related to a multi-country anti-malarial subsidy intervention.Capillary refill time as an independent prognostic indicator in severe and complicated malaria.FCGR2A functional genetic variant associated with susceptibility to severe malarial anaemia in Ghanaian children.Availability and price of malaria rapid diagnostic tests in the public and private health sectors in 2011: results from 10 nationally representative cross-sectional retail surveys.Drinking water quality and source reliability in rural Ashanti region, Ghana.Forming a supplement intervention using a multi-theoretical behavior model.The burden and correlates of hypertension in rural Ghana: a cross-sectional study.Cervical cancer screening in Ghana, west Africa: prevalence of abnormal cytology and challenges for expanding screening.A prospective comparison of malaria with other severe diseases in African children: prognosis and optimization of management.First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children.Routine lumbar puncture in children with febrile seizures in Ghana: should it continue?Otoacoustic emission testing in Ghanaian children with sickle-cell disease.Cardiac function in Ghanaian children with severe malaria.Source of medicines and medicine information by self-reported persons living with hypertension and diabetes in rural and urban GhanaAchieving the Global Goals in Sub-Saharan Africa
P50
Q28278852-7F4AA5A1-6434-476C-AA54-9A84F3F65BBDQ28740701-4A3CF86F-BB0C-4EC4-855D-CE7E325BFEA9Q28943391-3BEE752A-BC4A-4070-97E0-98A01FEEF599Q30575902-FF3D2E1E-D3E5-4831-B679-39DE35A42304Q30991737-A50FD765-6AF2-48E2-833C-DE2F4B3FA235Q33255848-1357F53C-9B82-4635-8524-18F5F9DEAFEDQ33289070-250F6231-8D21-469D-91AF-F0C8B2105EE7Q33508797-B5551886-C12C-4796-A96C-431E06994057Q33622597-246520D6-9392-481F-9C56-44568FE91A7DQ33712935-1723849A-726C-4543-9271-5F925A2C112CQ33721537-FC0724C1-BA79-4536-93DA-0C359AD3C0B3Q33794334-CE2448A5-80EC-49BB-B685-60AACB31560BQ33916803-36276CE8-3FCC-4A50-9FCA-219FA492ED5FQ33981953-4822D3A2-7FD3-49D3-A5BB-97B604B96295Q33982327-D5B767D8-E5BC-4BB5-90E1-23F80C5D4373Q34039470-EB35265C-5BFF-48AF-9760-DBDAF6421DD7Q34487139-DBD42DCB-28F7-46CF-9F82-55F80B3A21F8Q34533270-8B2F61A1-FD49-4216-9D55-291F17803671Q34651041-5B2A4184-6B60-405F-B1B1-895BACDC38A5Q35243451-FA18F868-AB51-4028-B3FD-EE96DC4A1262Q35534205-C85A0D05-62D0-417B-A256-BCAE71BADD22Q35645341-CDC2DA86-7062-4619-AB3A-692314E32C33Q36603519-D60B5698-E260-41FD-B8E1-BB1280800DC1Q37059334-C405A26B-0698-4D59-8262-9CC64F21D837Q37401660-75573CB2-95CD-470E-AD23-E64ED5E6CD15Q37583871-32A21C33-8AB9-4574-AB35-D15641D3A89DQ38996360-252C76D3-8FFD-4980-AC0F-7F1AE9512AE4Q39439776-07821CB7-F5E3-4D32-A795-8979087E7286Q40167408-DE88E08F-8BC6-4B5A-B128-6AC081ED59B4Q43355192-6CC6017F-5056-49DC-9955-614035F9B203Q43485317-6871D4E5-5BE4-4361-803C-73234ADB0586Q44220036-5FB99886-CAE0-47FA-BCD5-04815D040EEAQ44507567-E47B2082-EF11-42E6-9612-A9ACD2515DF0Q44586734-A3B700BE-13DC-4670-B2BA-CDCDF14E9BADQ46182948-B580F0CA-D083-4E87-9B81-1C630276FA2FQ46506100-F22D04DB-6061-436C-B499-14F7DBD3EB13Q46576394-1FE82832-15A1-4C54-B4B9-86DC4839759FQ48017295-4FA9025F-9192-48CF-AF78-AE66F79E62C0Q58724669-245E3D0D-A53C-494E-8A41-4BDA5E3407F7Q59154759-61D160D6-F571-4A40-A3B9-AB4E52319489
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel Ansong
@ast
Daniel Ansong
@en
Daniel Ansong
@es
Daniel Ansong
@nl
type
label
Daniel Ansong
@ast
Daniel Ansong
@en
Daniel Ansong
@es
Daniel Ansong
@nl
altLabel
Daniel ANSONG
@en
prefLabel
Daniel Ansong
@ast
Daniel Ansong
@en
Daniel Ansong
@es
Daniel Ansong
@nl
P106
P1153
6506910959
P21
P31
P496
0000-0003-1328-9117